钆塞酸二钠增强MRI评估肝纤维化:与瞬时弹性成像、ElastPQ及血清学纤维化标志物的比较
回顾性纳入67例肝活检或手术前接受钆塞酸二钠增强MRI及肝硬度测量的患者,比较MRI纤维化标志物、瞬时弹性成像、ElastPQ和血清学标志物评估肝纤维化分期的诊断效能。MRI的CEI与组织学分期负相关(r=-0.786),诊断≥F2和F4的AUC分别为0.898和0.881,优于APRI,与TE相仿,优于ElastPQ对≥F2的诊断。
要点
- CEI诊断≥F2和F4的AUC分别为0.898和0.881,优于APRI(0.699和0.715,均P<0.05)。
- CEI与TE诊断≥F2或F4的AUC无显著差异(均P>0.05),与ElastPQ仅≥F2有差异(P=0.021)。
- MRI纤维化标志物CEI、LSC、LPC、SIR均与组织学分期负相关(均P<0.001)。
核心结论
- 钆塞酸二钠增强MRI测量的CEI可对肝纤维化进行分期,诊断准确性与TE相仿,优于ElastPQ或APRI。
研究设计与样本
- 回顾性研究纳入67例患者(55男12女,平均年龄62.5岁),2014年1月至2018年1月于肝活检或手术前接受钆塞酸二钠增强MRI及肝硬度测量;以组织病理学纤维化分期为参考标准,比较TE、ElastPQ、血液检查及MRI纤维化标志物(CEI、LSC、LPC、SIR)的诊断效能。
关键影像表现/征象
- MRI纤维化标志物与组织学分期均呈负相关:CEI(r=-0.786)、LSC(r=-0.718)、LPC(r=-0.448)、SIR(r=-0.617),均P<0.001。
诊断标准与关键数值
- CEI诊断≥F2的AUC=0.898,诊断F4的AUC=0.881。
- APRI诊断≥F2的AUC=0.699,诊断F4的AUC=0.715;CEI优于APRI(均P<0.05)。
- TE诊断≥F2的AUC=0.866,诊断F4的AUC=0.884;CEI与TE无显著差异(均P>0.05)。
- ElastPQ诊断≥F2的AUC=0.751(与CEI比较P=0.021),诊断F4的AUC=0.786(与CEI比较P=0.234)。
临床应用与阅片要点
- 本研究所评估的MRI纤维化标志物包括CEI、LSC、LPC和SIR,其中CEI与组织学分期相关性最强且诊断准确性最高。
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the diagnostic performance of gadoxetic acid-enhanced magnetic resonance imaging (MRI), ultrasonography (US)-based elastography, and serologic fibrosis markers in assessing the stage of liver fibrosis.
MATERIALS AND METHODS: This retrospective study included 67 patients (55 male and 12 female; mean age 62.5 years) who underwent gadoxetic acid-enhanced MRI and liver stiffness measurements before liver biopsy or surgery between January 2014 and January 2018. Measurements were performed using transient elastography (TE), ultrasound shear wave elastography point quantification (ElastPQ), and blood tests. The following MRI-based fibrosis markers were assessed: contrast enhancement index (CEI), liver-spleen contrast ratio (LSC), liver-portal vein contrast ratio (LPC), and signal intensity ratio (SIR). The diagnostic performances of fibrosis markers were compared using the area under the receiver operating characteristic curve (AUC), with histopathologic fibrosis stage as the reference standard.
RESULTS: The fibrosis stages were F0-F1 (n = 17), F2 (n = 7), F3 (n = 20), and F4 (n = 23). MRI-based fibrosis markers negatively correlated with histologic stage: CEI (r = -0.786); LSC (r = - 0.718); LPC (r = - 0.448); and SIR (r = - 0.617; all P < 0.001). For diagnosis of either significant liver fibrosis (≥ F2) or cirrhosis (F4), the CEI provided better diagnostic accuracy (AUC = 0.898 and 0.881) than the aspartate aminotransferase-to-platelet ratio index (APRI) (AUC = 0.699 and 0.715; all P < 0.05). The CEI displayed similar diagnostic accuracy for ≥ F2 or F4 when using TE (AUC = 0.866 and 0.884, both P > 0.05) or ElastPQ [AUC = 0.751 (P = 0.021) and AUC = 0.786 (P = 0.234)].
CONCLUSIONS: The CEI measured by gadoxetic acid-enhanced MRI allows the staging of liver fibrosis, with a diagnostic accuracy comparable to that of TE and superior to that of ElastPQ or APRI.
引用
- Jang HJ, Min JH, Lee JE, et al. Assessment of liver fibrosis with gadoxetic acid-enhanced MRI: comparisons with transient elastography, ElastPQ, and serologic fibrosis markers. Abdom Radiol (NY). 2019. PMID: 31041497. doi:10.1007/s00261-019-02041-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。